Leerink Partnrs Has Bearish Forecast for AbbVie Q2 Earnings

AbbVie Inc. (NYSE:ABBV - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for AbbVie in a report issued on Sunday, July 6th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $2.87 per share for the quarter, down from their previous forecast of $3.24. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie's FY2025 earnings at $11.83 EPS and FY2027 earnings at $15.63 EPS.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The company had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same period in the previous year, the business earned $2.31 EPS. The firm's revenue was up 8.4% compared to the same quarter last year.

Other analysts have also issued research reports about the stock. The Goldman Sachs Group reiterated a "neutral" rating and issued a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. Bank of America lifted their price target on shares of AbbVie to $204.00 and gave the company a "hold" rating in a research note on Monday, June 9th. Evercore ISI increased their price objective on shares of AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Erste Group Bank raised AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. Finally, Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus price target of $211.29.

AbbVie Price Performance

Shares of ABBV opened at $189.60 on Wednesday. The firm has a market cap of $334.91 billion, a PE ratio of 80.68, a price-to-earnings-growth ratio of 1.25 and a beta of 0.48. AbbVie has a 52-week low of $163.81 and a 52-week high of $218.66. The business's 50 day moving average price is $187.19 and its two-hundred day moving average price is $188.77. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date is Tuesday, July 15th. AbbVie's payout ratio is 279.15%.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Steel Grove Capital Advisors LLC boosted its position in AbbVie by 1.7% in the fourth quarter. Steel Grove Capital Advisors LLC now owns 3,110 shares of the company's stock worth $553,000 after purchasing an additional 52 shares during the last quarter. FF Advisors LLC raised its stake in shares of AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company's stock worth $286,000 after purchasing an additional 53 shares during the period. Peninsula Wealth LLC boosted its holdings in shares of AbbVie by 4.1% in the 4th quarter. Peninsula Wealth LLC now owns 1,360 shares of the company's stock worth $242,000 after buying an additional 54 shares during the last quarter. Private Management Group Inc. grew its position in AbbVie by 1.9% during the first quarter. Private Management Group Inc. now owns 2,938 shares of the company's stock valued at $616,000 after buying an additional 54 shares during the period. Finally, Silicon Valley Capital Partners grew its position in AbbVie by 10.8% during the first quarter. Silicon Valley Capital Partners now owns 573 shares of the company's stock valued at $118,000 after buying an additional 56 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.